Tyk 2 Antibody (H-4): sc-166686

Tyk 2 Antibody (H-4) is a mouse monoclonal IgG2a antibody that detects Tyk 2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Tyk 2 is a crucial member of the non-receptor Janus tyrosine kinase family, playing a pivotal role in mediating cellular responses to cytokines and interferons, which are essential for the immune system′s functionality. Located primarily in the cytoplasm, Tyk 2 is recruited to activated cytokine receptors, where Tyk 2 phosphorylates signal transducer and activator of transcription (STAT) proteins. This phosphorylation triggers the dimerization of STATs, allowing STATs to translocate to the nucleus and regulate the transcription of genes involved in immune responses. Proper functioning of Tyk 2 is critical for maintaining immune homeostasis, as dysregulation can lead to various inflammatory diseases. Furthermore, Tyk 2′s involvement in the canonical JAK-STAT signaling pathway makes Tyk 2 an attractive target for therapeutic interventions aimed at modulating pro-inflammatory responses, highlighting Tyk 2′s significance in both basic research and clinical applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Tyk 2 Antibody (H-4) References:

1. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.  |  Burke, JR., et al. 2019. Sci Transl Med. 11: PMID: 31341059
2. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors.  |  Jo, CE., et al. 2022. Int J Dermatol. 61: 139-147. PMID: 33929045
3. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.  |  Gonciarz, M., et al. 2021. Immunotherapy. 13: 1135-1150. PMID: 34235974
4. Depression compromises antiviral innate immunity via the AVP-AHI1-Tyk2 axis.  |  Zhang, HG., et al. 2022. Cell Res. 32: 897-913. PMID: 35821088
5. TYK2 in Immune Responses and Treatment of Psoriasis.  |  Shang, L., et al. 2022. J Inflamm Res. 15: 5373-5385. PMID: 36147687
6. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.  |  Borcherding, DC., et al. 2023. Clin Cancer Res. 29: 1592-1604. PMID: 36799629
7. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.  |  Mease, P., et al. 2023. Arthritis Rheumatol. 75: 1370-1380. PMID: 37194394
8. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.  |  Chen, CX., et al. 2023. Cell Commun Signal. 21: 287. PMID: 37845748
9. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.  |  Wang, J., et al. 2023. bioRxiv.. PMID: 37873392
10. TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes.  |  Mine, K., et al. 2024. Nat Commun. 15: 1337. PMID: 38351043

The preferred Tyk 2 antibody is Tyk 2 Antibody (C-8): sc-5271.